摘要
目的探讨止嗽化痰颗粒联合布地奈德治疗慢性阻塞性肺疾病急性加重期(AECOPD)的临床疗效及对患者炎性因子、肺功能的影响。方法选取医院2016年2月至2018年11月收治的AECOPD患者100例,按随机数字表法分为对照组和研究组,各50例。两组患者均予抗感染及对症治疗,并予吸入用布地奈德雾化吸入,研究组患者加服止嗽化痰颗粒。两组均持续治疗14d。结果研究组总有效率为74.00%,显著高于对照组的52.00%(P<0.05);治疗后,研究组患者的用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、FEV1/FVC均显著高于对照组(P<0.05),血清白细胞介素6(IL-6)、C反应蛋白(CRP)、降钙素原(PCT)水平均显著低于对照组(P<0.05);对照组与研究组不良反应发生率相当(18.00%比22.00%,χ^2=0.250,P=0.617>0.05)。结论止嗽化痰颗粒联合布地奈德治疗AECOPD,可有效改善肺功能,降低机体炎性因子水平。
Objective To investigate the clinical efficacy of Zhisou Huatan Granules combined with budesonide in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD)and its effect on the inflammatory factors and pulmonary function.Methods Totally 100 patients with AECOPD admitted to our hospital from February 2016 to November 2018 were selected and divided into the control group and the study group according to the random number table method,50 cases in each group.The patients in the two groups were given anti-infection and corresponding symptomatic treatment,and inhaled Budesonide Suspension for Inhalation,on this basis,the patients in the study group were given Zhisou Huatan Granules.Both groups were continuously treated for 14 d.Results The total effective rate of the study group was 74.00%,which was significantly higher than 52.00%of the control group(P<0.05).After treatment,the forced vital capacity(FVC),forced expiratory volume in one second(FEV1)and FEV1/FVC in the study group were significantly higher than those in the control group(P<0.05),while the levels of serum interleukin-6(IL-6),C-reactive protein(CRP)and procalcitonin(PCT)in the study group were significantly lower than those in the control group(P<0.05).The incidence of adverse reactions in the control group was similar to that in the study group(18.00%vs.22.00%,χ^2=0.250,P=0.617>0.05).Conclusion Zhisou Huatan Granules combined with budesonide in the treatment of AECOPD can effectively improve the pulmonary function of patients and reduce the levels of inflammatory factors.
作者
程丽
冯高华
CHENG Li;FENG Gaohua(Department of Respiratory and Critical Care Medicine,Zhangjiagang Traditional Chinese Medicine Hospital,Zhangjiagang,Jiangsu,China 215600)
出处
《中国药业》
CAS
2020年第22期83-86,共4页
China Pharmaceuticals
关键词
止嗽化痰颗粒
布地奈德
雾化吸入
慢性阻塞性肺疾病
急性加重期
临床疗效
炎性因子
肺功能
Zhisou Huatan Granules
budesonide
inhalation
chronic obstructive pulmonary disease
acute exacerbation
clinical efficacy
inflammatory factors
pulmonary function
